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Background: With advances in hepatocellular carcinoma (HCC) screening and treatment, the incidence of
diagnosing a case of extrahepatic primary malignancy (EHPM) in patients with HCC has increased. This study aimed
to elucidate the prevalence and clinical outcomes of EHPM in patients with HCC who underwent curative resection
in Korea.
Methods: The clinical data of 250 patients with HCC who underwent curative resection in our hospital from May
2003 to December 2011 were retrospectively analyzed. The clinical features, overall survival, and causes of death
were compared between patients with HCC with or without EHPM.
Results: The prevalence of EHPM among the 250 patients was 13.2% (n = 33). The most common site of EHPM was
the colorectal (n = 10), followed by the stomach (n = 9), breasts (n = 4), and kidneys (n = 3). Patients with EHPM
were significantly older, and they presented with higher rates of comorbidities, a different etiology of HCC, and
better liver function than patients without EHPM. Interestingly, overall survival was significantly lower in the EHPM
group, which more frequently displayed extrahepatic causes of death. Moreover, the presence of EHPM was an
independent factor for overall survival in the study population.
Conclusions: The prevalence of EHPM in patients with HCC who underwent curative surgical resection was 13.2%
in Korea, with colorectal and stomach cancers comprising most EHPMs (88%). The patients with EHPM displayed
significantly worse survival because of extrahepatic causes of death, which should be considered in the
management of HCC in the future.
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Hepatocellular carcinoma (HCC) is the fifth common
cancer globally and the third leading cause of cancer
mortality [1]. Previously, extrahepatic primary malig-
nancy (EHPM) was rarely reported in patients with HCC
because of the poor prognosis of HCC. However, with
advances in early screening and therapeutic options for
HCC, EHPM is increasingly being diagnosed in the* Correspondence: jsh@snubh.org
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unless otherwise stated.clinic during the initial diagnosis of HCC or after cura-
tive treatment. Recent studies revealed that the inci-
dence of EHPM in patients with HCC has increased in
many countries in recent decades [2-12], and therefore,
proper screening and treatment strategies for EHPM in
patients with HCC represent an issue worthy of in-
creased attention.
Warren and Gates defined the criteria for multiple pri-
mary malignant neoplasia as follows: 1) each tumor
must definitively exhibit malignancy; 2) each tumor
must be distinct; and 3) the probability of a tumor being
a secondary metastatic lesion of the other tumor must
be reasonably excluded [13]. Therefore, EHPM tumorshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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able at the site of origin, and they must be correctly di-
agnosed histologically. Two previous studies including
subjects diagnosed between 1980 and the mid-1990s in
North America and Japan reported the prevalence (5.5–
8.9%) of EHPM in patients with HCC and diverse clin-
ical features [7,12]. Interestingly, the overall survival of
patients with HCC was not altered by the presence of
EHPM in either study, and death was more commonly
related to HCC rather than EHPM, suggesting the ex-
tremely poor prognosis of HCC negated the prognosis of
EHPM in most patients.
The epidemiology and etiology of HCC differ among
countries, and the prognosis of HCC is improving.
Moreover, a few studies of EHPM in patients with HCC
in the Asia-Pacific regions excluding Japan and Taiwan
have been reported [2,4,7,8,10,11,14-16]. This study
aimed to elucidate the prevalence, clinical characteris-
tics, and outcomes of EHPM in patients with surgically
resected HCC in Korea, where the major cause of HCC
is hepatitis B virus (HBV) infection [17].
Methods
Patients
In total, 270 patients with pathologically proven HCC
underwent surgical resection in Seoul National University
Bundang Hospital between May 2003 and December 2011.
Among them, 20 patients were excluded; 10 patients
underwent liver transplantation, 2 patients underwent pal-
liative surgery, and 8 patients displayed combined HCC
and cholangiocarcinoma. Therefore, the final study popula-
tion included 250 patients who underwent curative surgical
resection for HCC.
Methods
The clinical characteristics of the patients, presence of
EHPM, overall survival, and cause of death were retro-
spectively analyzed. Patient demographics, HCC eti-
ology, and biochemical laboratory data were retrieved
from electronic medical records. The etiology of HCC
was classified as HBV or hepatitis C virus (HCV) on the
basis of the serological presence of hepatitis B surface
antigen or anti-HCV antibody, respectively, or alcohol
on the basis of a history of alcohol intake of more than
80 g/day for men and 40 g/day for women for more than
10 years [18]. Survival and mortality, including the cause
of death, were confirmed by an examination of the final
medical records or via telephone calls to the participants
or their family members. Overall survival was defined as
the interval between the date of HCC surgery and the
date of death or the last follow-up. The mean follow-up
duration was 46.8 months (range 0–119 months). This
study was approved by the institutional review board of
Seoul National University Hospital.We diagnosed EHPM according to the criteria given
by Warren and Gates [13]. The EHPM group was fur-
ther subdivided to prior, synchronous, and metachro-
nous groups by using a 6-month interval between the
diagnoses of the primary and secondary cancers [7,12].
Prior EHPM was defined as EHPM diagnosed more than
6 months prior to the diagnosis of HCC, synchronous
EHPM was defined as EHPM diagnosed within 6 months
before or after the diagnosis of HCC, and metachronous
EHPM was defined as EHPM diagnosed more than
6 months after the diagnosis of HCC. Prior EHPM was
identified by evaluating the patients’ medical records or
history, and synchronous and metachronous EHPM
were detected by preoperative or postoperative screening
of radiological images and histological confirmation.
Statistical analysis
Descriptive data were presented as the mean ± standard de-
viation or number (percentage). The chi-squared test and
Student t-test were applied to analyze parametric data, and
the Fisher exact test and Mann–Whitney U test were used
for nonparametric data. The Kaplan-Meier method and
Cox regression analysis were applied for survival analyses.
All statistical results were analyzed by using SPSS version
20.0 (SPSS Inc., Chicago, IL, USA).
Results
Prevalence and clinical characteristics of EHPM in patients
with HCC
In total, 33 of 250 patients (13.2%) with surgically resected
HCC presented with EHPM. Of these, 32 patients had a sin-
gle EHPM, and the remaining patient had 2 EHPMs (stom-
ach and colon cancers). We divided the subjects according
to the presence (n = 33) and absence of EHPM (n = 217),
and compared the clinical and pathologic features of the
two groups. Compared to the non-EHPM group, the EHPM
group was significantly older, and patients in this group had
more comorbidity such as diabetes mellitus and hyperten-
sion, a lower proportion of HBV etiology, lower serum
levels of alanine aminotransferase, total bilirubin, and aspar-
tate aminotransferase (AST), and a lower AST to platelet ra-
tio index. However, tumor size, the frequency of vascular
invasion, and the pathologic TNM stage of HCC were not
significantly different between the 2 groups (Table 1).
The most common site of EHPM in patients with HCC
was the colorectal (30.3%), followed by the stomach
(27.3%), breasts (12.1%), and kidneys (9.1%). Prior, syn-
chronous, and metachronous EHPM were found in 7, 17,
and 9 patients, respectively (Figure 1). The detailed tumor
location, characteristics, pathologic TNM stage and applied
treatment modality for EHPM are described in Tables 2
and 3. Most patients with EHPM underwent curative sur-
gery (84.8%) and one third of EHPM group (33.4%) showed
advanced tumor stage (≥TNM stage 3).
Table 1 Clinical characteristics of 250 surgically resected HCC patients according to the existence of EHPM
Variables non-EHPM group (n = 217) EHPM group (n = 33) p-value
Age, yearsa, † 55.1 ± 11.1 63.1 ± 10.6 <0.001*
Male sexb 168 (77.4) 25 (75.8) 0.832
Diabetes mellitusb 36 (16.6) 12 (36.4) 0.007*
Hypertensionb 60 (27.6) 16 (48.5) 0.015*
Coexisting cirrhosisb 126 (58.1) 21 (63.6) 0.545
Etiology of liver diseaseb <0.001*
HBsAg (+) 167 (77.0) 16( 48.5)
Anti-HCV (+) 19 (8.8) 2 (6.1)
Alcohol 9 (4.1) 6 (18.8)
Other 22 (10.1) 9 (27.30)
CTP scoreb 1.000
A 206 (94.9) 32 (97.0)
B 11 (5.1) 1 (3.0)
MELD scorea 6.1 ± 3.4 5.4 ± 3.3 0.210
AST (IU/L)a 54.9 ± 74.1 33.6 ± 13.8 0.024*
ALT (IU/L)a 55.8 ± 90.1 31.3 ± 17.4 0.016*
Total bilirubin (mg/dL)a 1.5 ± 7.1 0.7 ± 0.3 0.020*
Serum albumin (g/dL)a 4.0 ± 0.5 3.9 ± 0.5 0.126
Platelet count (×103/μL)a 162.7 ± 72.7 171.2 ± 65.6 0.439
APRI scorea 1.1 ± 1.4 0.6 ± 0.3 0.034*
AFP (ng/mL)b 0.149
<20 109 (50.9) 20 (64.5)
20–200 41 (19.2) 5 (16.1)
>200b 64 (29.9) 6 (19.4)
pTNM stage of HCCb 0.259
I 106 (40.8) 19 (57.6)
II 77 (35.5) 11 (33.3)
III or IV 34 (15.7) 3(9.1)
Portal vein or major vessel invasionb 11 (5.1) 3 (9.1) 0.406
Microvessel invasionb 86 (39.6) 12 (36.4) 0.720
Tumor sizea 4.2 ± 2.8 3.8 ± 2.5 0.477
Follow-up duration (months)a 48.5 ± 26.2 36.0 ± 30.0 0.013*
Overall median survival (months) 46.0 27.0 0.178
HCC recurrenceb 114 (52.5) 10 (30.3) 0.017*
Time to recurrence (months)a 17.8 ± 16.8 21.4 ± 17.5 0.548
Number of deathsb 54 (24.9) 11 (33.3) 0.303
Time to death (months)a 29.8 ± 22.6 15.2 ± 15.3 0.045*
Cause of deathb 0.005*
Liver-related 50 (92.6) 6 (54.5)
Other 4 (7.4) 5 (45.5)
AFP, alpha-fetoprotein; ALT, alanine aminotransferase; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; CTP, Child-Turcotte-Pugh; EHPM, extrahepatic primary
malignancy; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; MELD, model for end-stage liver disease; pTNM stage, pathologic TNM stage.
amean ± standard deviation.
bpercent.
†At the time of HCC diagnosis.
*p < 0.05.
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Figure 1 Classification of 33 EHPM patients according to the location and diagnosis time of EHPM. (A) The most common site of
extrahepatic primary malignancy (EHPM) in patients with HCC was the colorectal (30.3%), followed by the stomach (27.3%), breasts (12.1%), and
kidneys (9.1%). (B) Prior, synchronous, and metachronous EHPM were found in 7, 17, and 9 patients, respectively. Prior EHPM was defined as
EHPM diagnosed more than 6 months prior to the diagnosis of HCC, synchronous EHPM was defined as EHPM diagnosed within 6 months
before or after the diagnosis of HCC, and metachronous EHPM was defined as EHPM diagnosed more than 6 months after the diagnosis of HCC.
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tive resection and did not display any recurrence of the
malignancy. Although not statistically significant, mor-
tality was highest in the synchronous EHPM group in
which extrahepatic causes of death were more frequently
observed.
Clinical outcomes of patients with HCC and EHPM
In total, 65 patients (26%) died during the mean follow-
up period of 46.8 months. The median overall survival
was 27 months in the EHPM group versus 46 months in
the non-EHPM group (p = 0.178). The cumulative prob-
abilities of overall survival at 1 year, 3 years, and 5 years
in the EHPM group were 45.5%, 9.1%, and 0%, respect-
ively, compared to 79.6%, 37.0%, and 11.1%, respectively,
in the non-EHPM group (Figure 2). To confirm the role
of EHPM in overall survival, univariate and multivariate
analyses of mortality were performed. The presence of
EHPM was an independent factor for mortality in multi-
variate analysis in addition to microvessel invasion and
alpha-fetoprotein levels exceeding 20 ng/mL (Table 4).
The recurrence rate of HCC was significantly higher in
the non-EHPM group. The cause of death was distinct
between the 2 groups. Almost all patients in the non-
EHPM group died of liver-related problems, whereas ap-
proximately half (5 of 11) patients in the EHPM group
died of non-liver–related causes, including EHPM pro-
gression (n = 2, 18%), brain hemorrhage (n = 1, 9%), sep-
sis (n = 1, 9%), and sudden cardiac arrest (n = 1, 9%).
Discussion
In this study, we demonstrated that the prevalence of
EHPM in patients who underwent curative resection forHCC in Korea was 13.2%, which was higher than that
reported previously. The most common locations of
EHPM were the colorectal, stomach, breasts, and kid-
neys. The overall survival of the EHPM group was sig-
nificantly worse than that of the non-EHPM group, and
the cause of death was non-liver–related in approxi-
mately half of the patients in the EHPM group. More-
over, EHPM was an independent factor for overall
survival in multivariate analysis.
Our study applied the criteria of Warren and Gates to
identify EHPM [13]. By using the same criteria, a North
American retrospective study found that 74 of 1349
(5.5%) patients with HCC also presented with EHPM be-
tween 1980 and 1993. The patients with EHPM tended
to be older and of the male sex, and the most common
EHPMs were prostate cancer (n = 16) and colorectal
cancer (n = 15). However, no significant difference in
mean survival according to the presence of EHPM was
noted [12]. A study in Japan also used the same criteria
and identified 41 EHPMs in 463 (8.9%) patients with
surgically resected HCC between 1979 and 1994. No sig-
nificant differences in clinical variables and survival were
noted between the EHPM and non-EHPM groups. In
this study, the most common EHPMs were gastric (n =
18) and colorectal (n = 9) cancers [7]. On the other hand,
the International Agency for Research on Cancer (IARC)
criteria for a second primary neoplasm are as follows: 1)
the existence of two or more primary cancers does not
depend on time; 2) a primary cancer is a cancer that
originates in a primary site or tissue and is not an exten-
sion, recurrence, or metastasis of another cancer; 3) only
one tumor shall be recognized as arising in an organ or
a pair of organs or tissues, which does not apply if the
Table 2 Clinical Characteristics and outcome of the HCC patients with EHMP
Variables Prior† EHPM
group (n = 7)
Synchronous† EHPM
group (n = 17)
Metachronous† EHPM
group (n = 9)
Total (n = 33) p-value
Age, yearsa, ‡ 64.3 ± 2.6 62.5 ± 2.8 63.3 ± 4.2 63.1 ± 1.8 0.936
Male sexb 4 (57.1) 14 (82.4) 7 (77.8) 25 (75.8) 0.487
Smoking, >10 pack-yearsb 3 (42.9) 6 (35.3) 3 (37.5) 12 (37.5) 1.000
Etiology of liver diseaseb 0.471
HBsAg (+) 5 (71.4) 6 (35.3) 5 (55.6) 16 (48.5)
Anti-HCV (+) 1 (14.3) 1(5.9) 0 (0.0) 2 (6.1)
Alcohol 0 (0.0) 5(29.4) 1 (11.1) 6 (18.2)
Other 1 (14.3) 5(29.4) 3 (33.3) 9 (27.3)
CTP scoreb 0.212
A 6 (85.7) 17 (100.0) 9 (100.0) 32 (97.0)
B 1 (14.3) 0 (0.0) 0 (0.0) 1 (3.0)
pTNM stage of HCCb 0.191
I 2 (28.6) 12 (70.6) 5 (55.6) 19 (57.6)
II 4 (57.1) 3 (17.6) 4 (44.4) 11 (33.3)
III or IV 1 (14.3) 2 (11.8) 0 (0.0) 3 (9.1)
AFP (ng/mL)b 0.470
<20 5 (71.4) 11 (68.8) 4 (50.0) 20 (64.5)
20–200 0 (0.0) 2 (12.5) 3 (37.5) 5 (16.1)
>200 2 (28.6) 3 (18.8) 1 (12.5) 6 (19.4)
Location of EHPMb
Esophagus 0 (0.0) 1 (5.9) 0 (0.0) 1 (3.0) 1.000
Stomach 4 (57.1) 4 (23.5) 1 (11.1) 9 (27.3) 0.152
Colorectal 1 (14.3) 6 (35.3) 3 (33.3) 10 (30.3) 0.697
Pancreas 0 (0.0) 0 (0.0) 1 (11.1) 1 (3.0) 0.485
Common bile duct 0 (0.0) 0 (0.0) 1 (11.1) 1 (3.0) 0.485
Breast 2 (28.6) 2 (11.8) 0 (0.0) 4 (12.1) 0.222
Thyroid 0 (0.0) 0 (0.0) 1 (11.1) 1 (3.0) 0.485
Kidney 1 (14.3) 2 (11.8) 0 (0.0) 3 (9.1) 0.579
Bladder 0 (0.0) 0 (0.0) 1 (11.1) 1 (3.0) 0.485
Prostate 0 (0.0) 0 (0.0) 1 (11.1) 1 (3.0) 0.485
Retroperitoneum 0 (0.0) 1 (5.9) 0 (0.0) 1 (3.0) 1.000
Bone marrow 0 (0.0) 1 (5.9) 0 (0.0) 1 (3.0) 1.000
pTNM stage of EHPM 0.166
0 0 (0.0) 1 (5.9) 0 (0.0) 1 (3.3)
1 4 (80.0) 8 (47.1) 1 (12.5) 13 (43.3)
2 1 (20.0) 4 (23.5) 1 (12.5) 6 (20.0)
3 0 (0.0) 3 (17.6) 5 (62.5) 8 (26.7)
4 0 (0.0) 1 (5.9) 1 (12.5) 2 (6.7)
Treatment of EHPMb 1.000
Operation 7 (100.0) 14 (82.4) 7 (77.8) 28 (84.8)
Radiation or Chemotherapy 0 (0.0) 1 (5.9) 1 (11.1) 2 (6.1)
Supportive care 0 (0.0) 2 (11.8) 1 (11.1) 3 (9.1)
Progression or recurrence of EHPMb 0 (0.0) 6 (35.3) 3 (33.3) 9 (27.3) 0.221
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Table 2 Clinical Characteristics and outcome of the HCC patients with EHMP (Continued)
Follow-up duration (months)a 18.4 ± 5.9 35.9 ± 6.7 49.8 ± 12.5 36.0 ± 5.2 0.115
Overall median survival (months) 18.0 32.0 38.0 28.0
Recurrence of HCCb 3 (42.9) 5 (29.4) 2 (22.2) 10 (30.3) 0.781
Deathb 2 (28.6) 7 (41.2) 2 (22.2) 11 (33.3) 0.628
Cause of deathb 0.697
Liver-related 1 (50.0) 3 (42.9) 2 (100.0) 6 (100.0)
Other 1 (50.0) 4 (57.1) 0 (0.0) 5 (100.0)
AFP, alpha-fetoprotein; CTP, Child-Turcotte-Pugh; EHPM, extrahepatic primary malignant neoplasm; HBsAg, hepatitis B surface antigen; HCC, hepatocellular
carcinoma; pTNM stage, pathologic TNM stage.
amean ± standard deviation, bpercent.
†Prior EHPM group, EHPM developed more than 6 months before the diagnosis of HCC; Synchronous EHPM group, EHPM developed within 6 months of the
diagnosis of HCC; Metachronous EHPM group, EHPM developed more than 6 months after the diagnosis of HCC.
‡At the time of HCC diagnosis.
*p < 0.05.
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second neoplasm must have a different histological type
than the primary lesion in the pathological diagnosis [19].
These rules have been adapted in studies with large registry
data, including a retrospective cohort study in China and a
nationwide cohort study in Taiwan, which may include
non-histologically proven tumors [2,3]. According to either
the IARC or Warren and Gates criteria, the prevalence of
EHPM in patients with HCC was 1.6–25.7% in previous
studies [2-12,14-16,20-23]. In our study, the prevalence of
EHPM was 13.2%, which was noticeably higher than those
reported in other Asian countries, in which the prevalence
is typically less than 10% [2-4,7,8,10,11,14-16]. Although
the reason for this higher prevalence is unclear, as many of
the previous studies were performed 20 years earlier than
our study, this difference could be related to the increasing
number of cancer survivors as a result of advances in early
detection and various treatment options for cancer.
Concerning the most common locations of EHPM in pa-
tients with HCC, colorectal cancer was the most prevalent
EHPM in this study, followed by gastric and breast cancers
[2]. In a study conducted in Spain, colorectal cancer was
the most prevalent EHPM in patients with HCC followed
by head and neck cancer and genitourinary cancer, in line
with the distribution of cancer in the general population of
Spain [5]. A report from South China unexpectedly identi-
fied nasopharyngeal cancer as the most prevalent EHPM in
patients with HCC, although the incidence of nasopharyn-
geal cancer was high in the region, emphasizing the need
for head and neck cancer screening among HCC survivors
[3]. On the contrary, Di Stasi et al. reported 10 immuno-
proliferative cancers of B-cell origin among 35 EHPMs
[21]. It is commonly suggested that the location of EHPM
is similar to that of the general population; in particular, the
Asian population has a high prevalence of gastric adenocar-
cinoma, whereas genitourinary and colorectal cancers are
most prevalent EHPMs in Western countries [2,5,12]. Our
data revealed colorectal cancer (30.3%) as the most popularEHPM in patients with surgically resected HCC followed
by stomach and breast cancers (21.2% and 12.1%, respect-
ively), suggesting that the location of EHPM in HCC also
follows the typical distribution of cancers in the general
population [24]. Therefore, gastric and colon cancer
screening should be considered for patients with newly di-
agnosed HCC.
In our study, the EHPM group was older, and these
patients presented with more accompanying comorbidi-
ties, various etiologies of liver disease, preserved liver
function, and lower recurrences of HCC but higher mor-
tality rates compared to the non-EHPM group. Some
studies reported a higher mean age for the EHPM group
[4,10,12], but this finding was not consistent [5,11]. Re-
cent reviews emphasized age as a risk factor for the de-
velopment of multiple primary malignant neoplasms
[25,26]. Accompanying chronic diseases such as diabetes
mellitus [7] or chronic kidney disease [2] have been re-
ported in other studies, and in this study, diabetes melli-
tus and hypertension were more common in the EHPM
group. Moreover, Andrykowski reported poorer mental
health status as well as an increased number of lifetime
comorbidities in patients with multiple primary cancers
compared to patients with a single cancer or no cancer
[27]. Therefore, integrated care including the treatment
of mental health problems and comorbidities is required
for patients with HCC and EHPM.
Although HBV was the predominant etiology in the
non-EHPM group (63.6%), the etiology differed greatly
in the EHPM group, which had a greater proportion of
cancers related to alcohol (18.8%) or of unknown eti-
ology (24.2%) and fewer cancers associated with HBV
(33.3%). This difference may be related to the older age
of patients in the EHPM group. This finding is compar-
able with those of other studies [8], but inconsistent re-
ports also exist [5,7]. Some studies reported a higher
prevalence of liver cirrhosis in the EHPM group [8,12],
although this finding is controversial [4,8,10].





pTNM stage† Follow up or survival
duration (months)
Cause
of deathbT N M Stage
1 Rectum S 3 0 0 IIA 118
2* Breast S 1 0 0 IA 4 H
3* Stomach S 3 3 1 IV 10 E
4* Stomach S 1 0 0 IA 21 E and O
5 Breast S 1 0 0 IA 53
6* Kidney S 1 0 0 I 0 H
7* Rectum S 3 2 0 IIIB 12 H
8 Esophagus S 1 0 0 IA 52
9 Kidney S 1 0 0 I 51
10 Colon S 3 0 0 IIA 48
11 Stomach (MALToma) S IEA(Ann Arbor) 47
12 Colon S 3 0 0 IIA 32
13 Colon S 3 0 0 IIA 28
14 Retroperitoneum S 2b 0 0 Ib 35
15* Multiple myeloma S III(ISS) 23 E
16 Stomach S is 0 0 0 17
17* Rectum S 3 1 0 IIIB 4 O
18* Rectum S 4b 2b 0 IIIC 3 H and E
19* Stomach M 3 0 0 IIA 16 H
20* Kidney P NA 18 H
21 Pancreas M 3 1 0 IIIB 55
22 Prostate M 3 0 0 III 74
23 Breast P 2 0 0 IIA 46
24 Colon P 2 0 0 I 27
Stomach P 1b 0 0 IA
25 Colon M 3 0 1 IVA 38
26 Colon M NA 24
27 Thyroid M 3 1a 0 III 29
28 CBD M 4 1 0 III 109
29 Stomach P 1 0 0 IA 17
30 Stomach P NA 0
31* Breast P 1 0 0 IA 1 O
32 Stomach P 1 0 0 IA 20
33 Bladder M. 1 0 0 I 100
CBD, common bile duct; EHPM, extrahepatic primary malignant neoplasm; HCC, hepatocellular carcinoma; is, in situ; NA, not applicable; pTNM stage, pathologic
TNM stage.
aM, metachronous group; P, prior group; S, synchronous group.
bH, HCC related; E, EHPM related; O, Others.
†Based on AJCC 7th edition, except Ann Arbor Staging for gastric lymphoma (MALToma) and ISS (International Staging System) for multiple myeloma.
*Patient who expired.
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significantly poorer survival of the EHPM group com-
pared to that of the non-EHPM group. To our know-
ledge, no previous study reported poorer survival for
patients with EHPM because the prognosis of HCC is
generally worse than that of EHPM [3,5-7,12]. Someprevious studies reported even higher overall survival for
the EHPM group [5,6]. In our study, both the cumulative
probability of survival and the result of multivariate ana-
lysis concomitantly support the poor survival of the
EHPM group. We cannot figure out the exact cause of
the poor outcome of EHPM group. However, several
Figure 2 Comparison of the overall survival between the HCC groups with and without EHPM. Using Kaplan Meier analysis, the
cumulative probabilities of overall survival at 1 year, 3 years, and 5 years in the EHPM group were 45.5%, 9.1%, and 0%, respectively, compared to
79.6%, 37.0%, and 11.1%, respectively, in the non-EHPM group. EHPM group showed poorer survival compared to non-EHPM group.
Table 4 Factors associated with mortality among 250 patients with HCC (surgically resected between May 2003 and
Dec 2011)
Variables Univariate analysis† Multivariate analysis†
HR 95% CI p value HR 95% CI p-value
Age > 60 years 0.967 0.578–1.616 0.897
Male sex 0.777 0.394–1.533 0.468
Diabetes mellitus 1.602 0.880–2.916 0.123
Hypertension 1.172 0.699–1.965 0.547
Alcohol drinking 0.676 0.405–1.128 0.134
Smoking, >10 pack-years 1.069 0.643–1.777 0.796
Portal vein or major vessel invasion 3.073 1.317–7.172 0.009* 1.066 0.361–3.151 0.908
Microvessel invasion 1.983 1.188–3.310 0.009* 1.850 1.058–3.236 0.031*
Intrahepatic metastasis 1.609 0.923–2.804 0.094
Alpha-fetoprotein > 20 ng/mL 1.806 1.083–3.014 0.043* 1.716 1.018–2.892 0.043*
Child-Turcotte-Pugh score B or C 0.840 0.361–1.955 0.686
Presence of EHPM 2.125 1.087–4.155 0.028* 2.002 1.016–3.942 0.045*
pTNM stage > II 2.303 1.285–4.129 0.005* 1.784 0.950–3.351 0.072
CI, confidence interval; EHPM, extrahepatic primary malignant neoplasm; HCC, hepatocellular carcinoma; HR, hazard ratio; pTNM score, pathologic TNM stage.
†According to the Cox proportional hazard model.
*p < 0.05.
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Hong et al. BMC Cancer  (2015) 15:146 Page 9 of 10characteristics could be found in the eleven expired pa-
tients of EHPM group. First, all of these eleven patients
lived no longer than two years. Second, their causes of
death were much more related with EHPM progression
or other reasons such as peritoneal seeding of stomach
cancer, progression of multiple myeloma, sepsis after op-
eration, sudden cardiac arrest or brain hemorrhage ra-
ther than liver related causes. Third, higher proportion
of advanced stages (stage 3 or 4) of EHPM existed in
these eleven patients. From these points, we can suppose
that EHPM could have hazardous effect on survival of
HCC patients and advanced stage of EHPM should be
alarmed in survival of HCC patients. Therefore, we can
suggest that surveillance for EHPM in HCC patients
should be reinforced and early detection and treatment
of EHPM possibly benefit the survival of HCC patients.
The limitations of this study were its retrospective design
and relatively small number of enrolled patients, in addition
to the inclusion of only patients with surgically resected
HCC. We could not recruit the details of the screening pat-
tern of EHPM of each patient. However, this study is the
first report of the clinical and pathological features and out-
comes of patients with HCC and EHPM in Korea, where
HBV is the most common cause of liver disease, in addition
to the country’s rapid socioeconomic development and im-
provements in the diagnosis and treatment of HCC.
Conclusions
In conclusion, the prevalence of EHPM in patients with
HCC who underwent curative resection for HCC in Korea
was 13.2%, which was higher compared to previous reports.
The overall survival of patients with HCC and EHPM was
significantly worse than that of patients with HCC without
EHPM. Therefore, considering the high prevalence of
EHPM and its adverse effect on overall survival, proper
screening strategy for early detection and treatment of
EHPM should be emphasized in patients with HCC.
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